BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31547718)

  • 1. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.
    Thapa B; Kc R; Bahniuk M; Schmitke J; Hitt M; Lavasanifar A; Kutsch O; Seol DW; Uludag H
    Hum Gene Ther; 2019 Dec; 30(12):1531-1546. PubMed ID: 31547718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery.
    Thapa B; Bahadur Kc R; Uludağ H
    Int J Cancer; 2018 Feb; 142(3):597-606. PubMed ID: 28960310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-SP5 Peptide-Modified Highly Branched Polyethylenimine for Gene Therapy of Gastric Adenocarcinoma.
    Li X; Xie Z; Xie C; Lu W; Gao C; Ren H; Ying M; Wei X; Gao J; Su B; Ren Y; Liu M
    Bioconjug Chem; 2015 Aug; 26(8):1494-503. PubMed ID: 26052814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
    Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
    Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.
    Aliabadi HM; Bahadur K C R; Bousoik E; Hall R; Barbarino A; Thapa B; Coyle M; Mahdipoor P; Uludağ H
    Acta Biomater; 2020 Jan; 102():351-366. PubMed ID: 31760224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
    Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
    Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL-secreting human mesenchymal stem cells engineered by a non-viral vector and photochemical internalization for pancreatic cancer gene therapy.
    Han J; Hwang HS; Na K
    Biomaterials; 2018 Nov; 182():259-268. PubMed ID: 30142525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small hydrophobe substitution on polyethylenimine for plasmid DNA delivery: Optimal substitution is critical for effective delivery.
    Thapa B; Plianwong S; Remant Bahadur KC; Rutherford B; Uludağ H
    Acta Biomater; 2016 Mar; 33():213-24. PubMed ID: 26802444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
    Xu Y; Liu D; Hu J; Ding P; Chen M
    Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
    Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo.
    Salmasi Z; Hashemi M; Mahdipour E; Nourani H; Abnous K; Ramezani M
    Biotechnol Prog; 2020 Nov; 36(6):e3025. PubMed ID: 32410328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient targeted pDNA/siRNA delivery with folate-low-molecular-weight polyethyleneimine-modified pullulan as non-viral carrier.
    Wang J; Dou B; Bao Y
    Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():98-109. PubMed ID: 24268238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
    Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
    Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
    Montazeri Aliabadi H; Landry B; Mahdipoor P; Uludağ H
    Mol Pharm; 2011 Oct; 8(5):1821-30. PubMed ID: 21838308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
    Aliabadi HM; Mahdipoor P; Uludağ H
    Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Cytotoxicity and Cytokine Production by Lipid-Substituted Low Molecular Weight Branched PEIs Used for Gene Delivery.
    Meenakshi Sundaram DN; Plianwong S; Kc R; Ostergaard H; Uludağ H
    Acta Biomater; 2022 Aug; 148():279-297. PubMed ID: 35738388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo.
    Zhang H; Sui A; Wang Z; Liu S; Yao R
    Int J Mol Med; 2012 Aug; 30(2):358-64. PubMed ID: 22614533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.